Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K0JQ
|
|||
| Former ID |
DCL000517
|
|||
| Drug Name |
Dilmapimod
|
|||
| Synonyms |
Dilmapimod; SB-681323; 444606-18-2; UNII-Q3238VQW0N; GW 681323; SB 681323; Q3238VQW0N; GW681323; SB681323; Dilmapimod [USAN:INN]; GSK 681323; Dilmapimod (USAN/INN); GTPL7815; SCHEMBL1065268; CHEMBL2103838; ORVNHOYNEHYKJG-UHFFFAOYSA-N; BCP23819; ZINC34997404; CS-6731; DB12140; SB16737; 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-Pyrido[2,3-d]pyrimidin-7(8H)-one; HY-10404; GW-681323; DB-070558; FT-0718750; J3.498.915J; D09602; SB-681323; GW-681323
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lung injury [ICD-11: NB32.3; ICD-10: J80; ICD-9: 518.5, 518.82] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
GSK
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H19F3N4O3
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)F)C2=C3C=CC(=O)N(C3=NC(=N2)NC(CO)CO)C4=C(C=CC=C4F)F
|
|||
| InChI |
1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
|
|||
| InChIKey |
ORVNHOYNEHYKJG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 444606-18-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7815). | |||
| REF 2 | ClinicalTrials.gov (NCT00291902) A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.